The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials

• Published in: Critical care (London, England) Vol. 27; no. 1; pp. 31 - 11
• Main Authors: Wang, Fengyun, Li, Yiming, Wang, Bingqing, Li, Jianguo, Peng, Zhiyong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.01.2023; BioMed Central; BMC
• Subjects: Acute lung injury; Acute respiratory distress syndrome; Animals; Bias; Biomarkers; Bone marrow; Care and treatment; Cell transplantation; Cells; Clinical trials; Collaboration; Coronavirus disease 2019; Coronaviruses; COVID-19; Critical care; Humans; Mesenchymal Stem Cells; Mesenchymal stromal cells; Meta-analysis; Mortality; Randomized Controlled Trials as Topic; Respiratory distress syndrome; Respiratory Distress Syndrome - therapy; Stem cells; Transplantation; Umbilical cord; Values; China; Acute respiratory distress syndrome; Mesenchymal stromal cells; Acute lung injury; Coronavirus disease 2019; Cell transplantation

Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 pandemic, MSC was intensely studied for treating COVID-19-induced ARDS. The purpose of this study is to evaluate the safety and...